Alejandro JaraCristobal CuadradoEduardo A. UndurragaChristian GarcíaManuel NájeraMaría Paz BertogliaVerónica VergaraJorge FernándezHeriberto García-EscorzaARAOS BRALIC, RAFAEL IGNACIORAFAEL IGNACIOARAOS BRALIC2024-02-062024-02-062023Jara, A., Cuadrado, C., Undurraga, E. A., García, C., Nájera, M., Bertoglia, M. P., Vergara, V., Fernández, J., García-Escorza, H., & Araos, R. (2023). Effectiveness of the second COVID-19 booster against Omicron: A large-scale cohort study in Chile. Nature Communications, 14(1), 6836. https://doi.org/10.1038/s41467-023-41942-yhttps://hdl.handle.net/11447/8757https://investigadores.udd.cl/handle/123456789/839310.1038/s41467-023-41942-y2-s2.0-85175085315WOS:001088086300001<jats:title>Abstract</jats:title><jats:p>In light of the ongoing COVID-19 pandemic and the emergence of new SARS-CoV-2 variants, understanding the effectiveness of various booster vaccination regimens is pivotal. In Chile, using a prospective national cohort of 3.75 million individuals aged 20 or older, we evaluate the effectiveness against COVID-19-related intensive care unit (ICU) admissions and death of mRNA-based second vaccine boosters for four different three-dose background regimes: BNT162b2 primary series followed by a homologous booster, and CoronaVac primary series followed by an mRNA booster, a homologous booster, and a ChAdOx-1 booster. We estimate the vaccine effectiveness weekly from February 14 to August 15, 2022, by determining hazard ratios of immunization over non-vaccination, accounting for relevant confounders. The overall adjusted effectiveness of a second mRNA booster shot is 88.2% (95%CI, 86.2–89.9) against ICU admissions and 90.5% (95%CI 89.4–91.4) against death. Vaccine effectiveness shows a mild decrease for all regimens and outcomes, probably linked to the introduction of BA.4 and BA.5 Omicron sub-lineages and the waning of immunity. Based on our findings, individuals might not need additional boosters for at least 6 months after receiving a second mRNA booster shot in this setting.</jats:p>bnt162 vaccinechilecohort studiescovid-19humanspandemicsprospective studiesrna, messengersars-cov-2sars-cov-2 variantschilecoronavactozinameranvaxzevriabnt 162 vaccinecoronavacmessenger rnacovid-19immunizationrnavaccinationvaccineadultarticlechilecohort analysisconfounding variablecontrolled studycoronavirus disease 2019drug efficacyfemalehospital admissionhumanimmunizationintensive care unitmajor clinical studymaleprospective studysars-cov-2 omicroncoronavirus disease 2019pandemicsevere acute respiratory syndrome coronavirus 2Resource Types::text::journal::journal article